Paclitaxel or Nab-Paclitaxel

DRUG3 trials

Sponsors

MedImmune LLC, Shanghai Henlius Biotech

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)Selected Advanced Solid TumorsSquamous NSCLC

Phase 1

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Active, not recruitingNCT03530397

MedImmune LLCSelected Advanced Solid Tumors

Start: 2018-04-24End: 2027-11-30Updated: 2026-08-21

Phase 2

A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

Not yet recruitingNCT07318883

Shanghai Henlius BiotechSquamous NSCLC

Start: 2026-03-31End: 2031-01-31Target: 720Updated: 2026-01-06

A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Not yet recruitingNCT07865910

Shanghai Henlius BiotechNSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2026-11-30End: 2031-12-30Target: 1438Updated: 2026-10-08

Related Papers

Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibody.

2026-02-17

Dual Target-Mediated Drug Disposition Model to Guide the Selection of Starting Dose and Escalation in FTIH Trials for Volrustomig (MEDI5752), a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4

2025-02-18

eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT).

Journal of Clinical Oncology2024-06-018 citations

eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.

Journal of Clinical Oncology2024-06-017 citations

Abstract CT016: MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study

Cancer Research2022-06-153 citations

Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial.

Journal of Clinical Oncology2022-06-0117 citations